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Abstract
Background A rise in cosmetic procedures has seen the
use of fillers become more prevalent. Complications
resulting from use of fillers have prompted introduction of
various medical and surgical interventions. Recently, stem
cell therapies have become more widely used as a new
treatment option for tissue repair and regeneration.
Methods We utilized adipose-derived stem cells (ASCs)
for tissue regeneration in patients with filler-related com-
plications such as necrosis. All 12 patients were treated
with ASCs and some patients had additional treatment.
After relief of symptoms, wound surface area was com-
pared in terms of pixel numbers and scar condition was
evaluated using the Vancouver Scar Scale (VSS).
Results In general, we achieved satisfactory resolution of
filler-related complications in a short period of time with-
out serious side effects. The average number of days from
stem cell treatment to symptom relief was 7.3 days. The
proportion of wound surface area from photographic record
was 4.39 % before treatment, decreasing considerably to
1.01 % following treatment. Last, the VSS showed almost
all patients scored below 3, with two patients receiving
scores of 7 and 8; the average score was 2.78 (range from 0
to 8).
Conclusions ASCs are a new treatment option for post-
filler injection wounds such as necrosis. Using stem cells,
we were able to obtain satisfactory results in a short period
of time without complications requiring surgical proce-
dures. We suggest stem cell injections could be used as the
first option for treatment of complications from filler
injections.
Level of Evidence V This journal requires that authors
assign a level of evidence to each article. For a full
description of these Evidence-Based Medicine ratings,
please refer to the Table of Contents or the online
Instructions to Authors www.springer.com/00266.
Keywords Adipose-derived stem cells  Necrosis  Tissue
repair  Filler complication
Introduction
Use of soft tissue fillers to restore volume to depressed
areas of skin for maintenance of a youthful appearance has
been widespread in recent years. Such use is very popular
because of its simplicity, low invasiveness, and procedure
reversibility, as well as a relatively safe profile. However,
as use of fillers has increased, so too has the number of
reported complications. These complications, such as vas-
cular compromise and skin necrosis, are often significant
and permanent.
Use of stem cells with regenerative potential, such as
embryonic or mesenchymal stem cells, has recently
emerged as a new form of therapy for wound management.
Stem cells are multipotent and possess the ability to self-
renew. They are thought to help heal wounds by stimu-
lating angiogenic processes and secreting angiogenic fac-
tors; however, the exact mechanisms remain unknown. A
newer type of adult stem cell, derived from adipose cells
within fat tissue, was discovered at the end of the 20th
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century. These stem cells are known as adipose-derived
stem cells (ASCs) [1].
We have observed many patients with complications
following the use of soft tissue fillers. Despite attempts at
remediation with various treatments, including dressing
with various materials, surgical debridement, skin grafts
and local flaps; unsightly skin loss, scarring, and asym-
metry still occurred. Therefore, in an effort to maximize
rapid recovery and minimize adverse sequelae, we exam-
ined the use of stem cell therapy at an early stage of wound
development in patients who had received filler injections.
Materials and Methods
Patients
Of the 53 patients who visited our clinic for complications
following facial filler injections, during the period from
2010 to 2014, we retrospectively analyzed 12 people who
had been treated with ASC injection.
These patients, who had filler injections on the glabella
or nose, presented with various symptoms including ery-
thema, pustules, skin necrosis, eschar formation, and
blindness.
Patient Review and Treatment Procedure
This study was performed using a medical chart review
method that included analyzing demographic data (male/
female, mean age), type of filler injection, injection area,
symptoms and signs, time interval between filler injection
and stem cell treatment, treatment period, remaining
complications, and additional secondary treatments. All 12
patients were treated with injections of ASCs and some
patients had additional treatment such as antibiotics or
steroids. The authors compared wound surface area before
treatment and after relief of symptoms related to mild
complications (erythema, hypopigmentation, scar, etc.).
From photographs, wound surface area was calculated in
terms of pixel numbers displayed by the ImageJ program
(US National Institutes of Health, Bethesda, MD, USA),
with values compared before and after ASC treatment. Scar
condition was also evaluated in nine patients (three patients
were lost at follow-up) using the Vancouver Scar Scale
(VSS).
Preparation of ASCs for Injection
A harvesting cannula, with a blunt tip attached to a 50-ml
Luer-Lok syringe, was inserted into a 3-mm abdominal
incision and adipose tissue was harvested from patients’
abdomens by liposuction using a Lipokit (Medikan Inc.,
Seoul, Korea) to extract stem cells. Harvested fat tissue
collected in the syringe was subsequently subjected to
adipo-dissociation. First, fat tissue was centrifuged for
4 min at 3500 rpm, resulting in approximately 20 cc of
adipose tissue separating into layers, which were then
mixed with collagenase Type II (Worthington Industries,
Columbus, OH, USA) and liquefied with 20 cc of saline
solution. During this process, collagenase Type II is
essential for effective recovery of cells from adipose tissue
by enzymatic digestion [2]. Adipose tissue and collagenase
Type II were then incubated in a Luer-Lok syringe for
30 min at 37 C using a Maxstem kit (Medikan Inc.) before
centrifugation for 3 min at 3500 rpm. Subsequently, 2 cc
of solution collected from the bottom fraction was treated
with 950 cc of Hartmann solution, and 50 cc of 5 % dex-
trose saline and washing solution with gentamicin. After
three repetitions of this centrifugation and wash procedure,
a 2-cc stroma-vascular fraction (SVF) pellet was obtained.
Two milliliters of a solution containing ASCs, endothelial
cells, endothelial progenitor cells, pericytes, smooth mus-
cle cells, leukocytes, and erythrocytes were divided into
1-ml syringes [3]. This final solution was injected into the
lesion at subcutaneous and dermis layers near the wound
[4].
After injection of ASCs, ointment-impregnated gauze
with topical antibiotics was applied to the raw surface. This
dressing was changed at approximately the same time
every day until wounds were epithelized. Patients received
management for scar prevention using a silicone gel sheet
and ointment after total healing.
Results
Characteristics of the study population are shown in
Table 1. Twelve female patients, average age of 35.6 years
(24–52 years), received ASC therapy for adverse reactions
to filler injections they had received from 2009 to 2014.
Cell counts for SVF samples used in treatments were about
1 9 105 cells per ml, as determined by hemocytometry
(Fig. 1).
All patients had filler injections on the nasal area, with
three patients also having had injections on the glabella,
which were all separately performed by a total of four
plastic surgeons, five general practitioners and dermatolo-
gists, and three non-practitioners. Chief complaints from
patients were erythema, necrosis, swelling, pustules, and
blindness. Necrosis was noted in ten cases, erythema in
eight cases, and blindness in three cases. The average
interval between filler injection and stem cell treatment for
11 of the 12 patients was 5 days. One of the 12 patients had
delayed stem cell treatment, visiting the clinic 3 months
after her filler injection, resulting in an overall interval
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range of 3–90 days and an average of 13.7 days. Antibiotic
administration was the most common additional treatment
(11 cases). The average number of days it took from stem
cell treatment administration to relief of symptoms in nine
patients was 7.3 (2–22 days). Three cases could not be
assessed because they were not able to be followed up after
treatment.
We observed seven cases of mild scarring, three cases of
erythema, and one case of hypopigmentation. However, all
wounds healed in a short period of time without serious
side effects (Figs. 2, 3, 4). To minimize remaining com-
plications, five patients received a secondary stem cell
treatment and one patient required a composite graft for
nostril notching. To achieve objective comparison between
remaining lesions and original wound sites, pixels were
calculated from photographs of the lesion, as previously
described. Briefly, ImageJ software was used, by two
unrelated physicians, to calculate the number of pixels of
Table 1 Patient and stem cell treatment profile
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necrosis
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PS plastic surgeon, GP general practitioner, Derma dermatologist, F/U loss follow-up loss
Fig. 1 The extracted SVF samples were sent to laboratory for cell
counting using a hemocytometer. There were about 1 9 105 cells per
1 ml of SVF
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evident wound and complication sites before and 6 months
after treatment. The proportion of wound surface area to
total photographic pixels was 4.39 % before treatment,
decreasing substantially to 1.01 % after treatment with
ASCs (Table 2). Using the Vancouver Scar Scale (VSS),
two physicians evaluated scar condition in nine patients
who completed the study at 6 months post-treatment.
The VSS consists of four parameters: pigmentation,
vascularity, pliability, and height. The highest score on this
scale is 13, indicating the worst condition of a scar,
whereas a lower score indicates an improved scar condi-
tion. Almost all of the patients scored below 3, with two
patients receiving scores of 7 and 8; the average score was
2.78 (range from 0 to 8).
Discussion
Since the first autologous fat injection for face volume
restoration was performed [5], many fillers (e.g., bovine
collagen [Zyderm, Zyplast], Restylane, etc.) have been
developed and approved by the Food and Drug Adminis-
tration. As corresponding usage of fillers has increased,
reported cases of adverse effects have also increased; all
fillers can carry a degree of risk of mild to severe com-
plications. Mild adverse effects include swelling, erythema,
and nodules; moderate effects include infection and scars,
whereas serious adverse effects include blanching resulting
from vascular compromise and necrosis. The most severe
complication from filler injections is skin necrosis. A few
hypotheses explain mechanisms underlying necrosis,
such as allergic reaction (hypersensitivity), external
Fig. 2 A 42-year-old woman developed skin necrosis of the nose
following a filler (Cutegel) injection into the nasal dorsum and tip.
Nine days after debridement and stem cell injection, necrotic tissue
almost disappeared, and partial raw surface was showing. After
2 months, except for erythema, the wound was healing well. One year
after treatment, remnant scar was still showing, but the erythema had
decreased considerably
Fig. 3 A 35-year-old female developed necrotic changes following a
filler (unknown) injection into the nasal dorsum and tip. Three days
after the filler injection, the patient came to the clinic with erythema
and necrosis. Stem cell therapy was started, and after 3 days, necrotic
tissue disappeared and partial raw surface was showing on the nasal
tip. One week after stem cell injection, mild erythema remained, and
after 7 weeks, the wound had healed into normal skin
Fig. 4 A 23-year-old female patient came to hospital suffering from
pain, edema, skin necrosis, and pus discharge following a filler
injection (Artecoll) into the forehead, nasal ridge, and tip. Seven days
after debridement and stem cell injection, the wound had totally
healed except for mild erythema and scarring. One month later, the
scarring and erythema showed no considerable change, but after
6 months, no complications were shown
Table 2 Comparison of areas between wound site before treatment
and after treatment
Patient Pixels of wound or complication
area/total pixels of photograph (%)
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compression, and intra-arterial injection; however, artery
embolism induced by intra-arterial injection is the most
accepted theory. Whereas most complications are transient,
more severe adverse events, including necrosis, can leave
patients with long-lasting or permanent aesthetic and
functional problems [6].
Although it is important to treat complications when
they are observed, prevention is a far better way to deal
with complications. When injecting filler, rapid flow rate
and high volume are risk factors for increased side effects.
Therefore, adequate amounts of filler should be injected
slowly to get low pressure. Small-caliber and blunt needles
should be used, while aspiration prior to injection is nec-
essary to reduce the rate of tissue necrosis. Despite all
efforts, if an unavoidable complication occurs, appropriate
treatment should be performed as soon as possible.
According to the treatment algorithm for complications
after filler injections [7], treatments vary depending on
symptoms. Moreover, treatment is decidedly different for
wounds, which are defined as a disruption of normal ana-
tomic structure and functional integrity of the skin. Usu-
ally, debridement, antibiotic therapy, and hyperbaric
oxygen therapy are carried out for wounds extending deep
into the dermis that also present with necrotic tissue.
However, when these repair strategies are ineffective, other
methods, such as skin grafts, should be considered. These
treatments can result in protracted healing and sequelae,
such as scars, contractures, and pigmentation, according to
our experience. As wound healing has been linked to
release of cytokines, chemokines, and growth factors, stem
cell therapy is emerging as a new treatment of great
interest. Further, since debridement, skin grafts and similar
treatments are highly invasive and extremely destructive,
our institution has been applying stem cell therapies more
frequently to facilitate wound healing. Because of their
multipotency, ASCs can be used in a wide variety of
clinical applications such as diabetic or chronic radiation
ulcers, which are difficult to resolve.
In addition, we applied ASCs in blindness cases. In our
research, blindness was reported in three cases with
symptoms improving after ASCs were administered at the
retrobulbar area. General treatment for blindness includes
ophthalmologic evaluations such as consultation and
angiography. And aspirin administration, hyaluronidase
injection, and oxygen therapy can be possible treatments.
But our results indicate when early detection of blindness
and rapid application of ASCs is possible, we suggest
ASCs as an optional treatment. Compared with other
available treatments, ASCs are generally harmless. Further,
considering all three patients showed a favorable response
to the treatment, ASC application can be a useful method
for treating symptomatic blindness. But, further evaluation
is necessary.
Most patients treated in this center were injured at a
level deeper than the subcutaneous layer and indirect
comparison was performed due to lack of a control group.
According to one study investigating wound healing with
bFGF treatment in second-degree burn patients, wound
healing in the bFGF group took 12.0 ± 2.2 days compared
to 15.0 ± 2.7 days for control groups using ointment and
gauze [8]. Additionally, Kazakos et al. suggested treatment
duration of soft tissue wounds using autologous PRP took
21.26 ± 1.35 days on average among 27 patients applying
PRP [9]. In contrast, we were able to successfully relieve
symptoms without major complications in a reasonably
short time span (average of 7.3 days), although results
varied depending on severity of symptoms at the patient’s
first presentation. Compared with normal wound healing or
a PRP (platelet-rich plasma) wound healing process, early
direct movement of stem cells allows wound healing
without blood clots or scab formation through direct dif-
ferentiation to dermis, vessels, and epidermis (Fig. 5).
In this article, there was no control group treated for
filler complications with other methods, making a direct
comparison of treatment periods difficult. Also, although
most patients displayed necrosis when ASC treatment
commenced, variation in the extent of necrosis resulted in
differences of duration for symptom relief, scar condition,
and post-treatment results. Accordingly, severity of
necrosis is an important factor for competent treatment.
Our study is also limited by a relatively small group of 12
patients. If there had been more patients alongside a control
group with general dressing, a more objective and defini-
tive result could be assumed. Nevertheless, with our own
results and what is known from other studies on this topic,
we can conclude that starting stem cell therapy early is
helpful for symptom relief in 12 patients with adverse
reactions to filler injections. In addition, when comparing
the number of pixels between the two sites—before treat-
ment and complications remaining after treatment—and
evaluating scar condition with the VSS, we found that stem
cell therapy objectively results in reduced scar formation
without major complications. In the future, an appropriate
concentration of stem cells should be administered
according to wound severity and based on research
regarding exact stem cell mechanisms.
Conclusions
Filler injections are seen as an easy way to restore volume
to a depressed area of the skin. However, numerous com-
plications following filler injections have been reported,
with various treatments introduced to address these issues.
ASCs are a new treatment option for post-filler injection
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wounds such as necrosis, erythema, and scar formation.
Using stem cells in a limited study, we were able to obtain
satisfactory results in a short period of time without any
sequelae requiring surgical procedures. Before ASCs were
introduced, the treatment of choice for small defects was
surgical intervention according to a reconstruction ladder.
Our results suggest stem cell injections could be used as the
first option for treatment of complications from filler
injections.
In conclusions, early-condensed adipose-derived stem
cell injections may resolve various complications, such as
necrosis following a filler injection to the face, by pro-
moting rapid re-epithelization, angiogenesis, and regener-
ation of soft tissues.
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